Pitcairn Co. Reduces Stock Position in Becton Dickinson and Co (NYSE:BDX)

Pitcairn Co. trimmed its position in Becton Dickinson and Co (NYSE:BDX) by 69.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 900 shares of the medical instruments supplier’s stock after selling 2,018 shares during the quarter. Pitcairn Co.’s holdings in Becton Dickinson and were worth $216,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of BDX. Elefante Mark B raised its position in shares of Becton Dickinson and by 21.9% in the 2nd quarter. Elefante Mark B now owns 2,847 shares of the medical instruments supplier’s stock worth $681,000 after acquiring an additional 512 shares in the last quarter. CIBC Asset Management Inc raised its position in shares of Becton Dickinson and by 73.7% in the 2nd quarter. CIBC Asset Management Inc now owns 41,847 shares of the medical instruments supplier’s stock worth $10,013,000 after acquiring an additional 17,760 shares in the last quarter. Raymond James & Associates raised its position in shares of Becton Dickinson and by 3.0% in the 2nd quarter. Raymond James & Associates now owns 710,135 shares of the medical instruments supplier’s stock worth $169,928,000 after acquiring an additional 20,364 shares in the last quarter. Middleton & Co Inc MA raised its position in shares of Becton Dickinson and by 20.4% in the 2nd quarter. Middleton & Co Inc MA now owns 1,957 shares of the medical instruments supplier’s stock worth $468,000 after acquiring an additional 331 shares in the last quarter. Finally, Close Asset Management Ltd raised its position in shares of Becton Dickinson and by 12.4% in the 2nd quarter. Close Asset Management Ltd now owns 131,529 shares of the medical instruments supplier’s stock worth $31,479,000 after acquiring an additional 14,520 shares in the last quarter. Institutional investors and hedge funds own 85.44% of the company’s stock.

In other news, EVP Patrick Kaltenbach sold 1,049 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $243.20, for a total value of $255,116.80. Following the sale, the executive vice president now owns 12,661 shares in the company, valued at $3,079,155.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.12% of the stock is owned by corporate insiders.

Shares of BDX stock opened at $281.34 on Friday. The stock’s 50-day simple moving average is $250.93 and its 200-day simple moving average is $250.95. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.66 and a current ratio of 0.98. The firm has a market capitalization of $76.29 billion, a PE ratio of 24.27, a P/E/G ratio of 3.74 and a beta of 0.93. Becton Dickinson and Co has a fifty-two week low of $197.75 and a fifty-two week high of $286.72.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.23. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The business had revenue of $4.25 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the prior year, the company earned $2.59 earnings per share. The company’s revenue was up 1.4% on a year-over-year basis. Sell-side analysts forecast that Becton Dickinson and Co will post 10.35 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.12%. Becton Dickinson and’s payout ratio is 27.05%.

Several research firms have recently commented on BDX. KeyCorp reissued a “hold” rating on shares of Becton Dickinson and in a research report on Tuesday, May 12th. Raymond James reduced their target price on Becton Dickinson and from $290.00 to $265.00 and set an “outperform” rating on the stock in a research report on Thursday, June 25th. SVB Leerink upped their target price on Becton Dickinson and from $262.00 to $277.00 and gave the company a “market perform” rating in a research report on Wednesday, July 15th. Morgan Stanley reduced their target price on Becton Dickinson and from $255.00 to $248.00 and set an “equal weight” rating on the stock in a research report on Thursday, June 25th. Finally, Cfra reduced their target price on Becton Dickinson and from $285.00 to $278.00 and set a “hold” rating on the stock in a research report on Friday, May 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $275.06.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Diversification in Investing

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.